Skyrizi 150mg Injektionslösung im Fertigpen Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

skyrizi 150mg injektionslösung im fertigpen

abbvie ag - risankizumabum - injektionslösung im fertigpen - risankizumabum 150 mg, natrii acetas trihydricus corresp. natrium 0.209 mg, acidum aceticum glaciale, trehalosum dihydricum, polysorbatum 20, aqua ad iniectabile ad solutionem pro 1 ml. - plaque-psoriasis bei erwachsenen; psoriasis-arthritis - biotechnologika

Survanta Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

survanta

abbvie deutschland gmbh & co. kg - zweigniederlassung - (8146051) - phospholipide aus rinderlunge - suspension - phospholipide aus rinderlunge (01490) 72,8 milligramm

Ganfort Europäische Union - Deutsch - EMA (European Medicines Agency)

ganfort

abbvie deutschland gmbh & co. kg - bimatoprost, timolol - glaucoma, open-angle; ocular hypertension - ophthalmika - reduzierung der intraokulare druck (iop) bei patienten mit offenwinkelglaukom und okulärer hypertension, die unzureichend auf topischen betablocker oder prostaglandin analoga reagieren.

Venclyxto Europäische Union - Deutsch - EMA (European Medicines Agency)

venclyxto

abbvie deutschland gmbh co. kg - venetoclax - leukämie, lymphozytär, chronisch, b-zell - antineoplastische mittel - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.